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S U M M A R Y
Objectives: To investigate the distribution and risk factors associated with drug-resistant tuberculosis
(TB) at a local hospital in Northeast China.
Methods: A total of 205 patients with TB were enrolled in the study from March 8, 2010 to July 13, 2011.
Mycobacterium tuberculosis (MTB) strains isolated from patients were subjected to drug susceptibility
testing by proportion method.
Results: Among the 205 patients with MTB, 54 (26.3%) had isolates that showed resistance to at least one
drug. The overall prevalence of multidrug-resistant TB (MDR-TB) was 6.8% (n = 14) (3.0% of newly
diagnosed patients and 22.0% of previously treated cases). Importantly, an extensively drug-resistant TB
(XDR-TB) isolate was found, which was isolated from a newly treated patient. Eleven (5.4%) were
infected with a poly-resistant strain of MTB (5.5% of newly diagnosed patients and 4.9% of previously
treated cases). The mono-resistance rates of isoniazid, rifampin, ethambutol, streptomycin, oﬂoxacin,
and kanamycin were 3.4%, 1.5%, 2.4%, 3.9%, 2.4%, and 0.5%, respectively. Certain groups, including
previously treated patients and male patients, were more likely to develop drug-resistant TB.
Conclusions: The results of this analysis of drug resistance in MTB reﬂect the situation in a local hospital
and indicate that the morbidity related to TB, especially MDR-TB, is still a serious health problem. Thus,
the timely detection of drug resistance is of great importance to optimize treatment and to direct
infection control measures to block the transmission of MDR-TB.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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The emergence of drug-resistant tuberculosis (TB), especially
multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB), has become a signiﬁcant public
health problem on a global scale (particularly in developing
countries).1–4 In 2011, an estimated 450 000 (5.2%) of the world’s
8.7 million prevalent cases of TB had MDR-TB.3 China has one of the
highest TB burdens in the world. Based on the data of the ﬁfth
national TB epidemiological survey in 2010, there were about 1.4
million TB patients in China,5 accounting for 12% of the global
cases. Furthermore, the observed MDR-TB prevalence was 7.6%
(standard deviation (SD) 1.6%) in 2000 and this fell to 5.4% (SD* Corresponding author. Tel.: +86 20 87113848; fax: +86 20 87112734.
E-mail address: yanhe@scut.edu.cn (H. Yan).
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http://dx.doi.org/10.1016/j.ijid.2013.12.0151.6%) in the 2010 prevalence survey. The estimated number of
prevalent MDR-TB cases in the general population fell from
164 000 (95% conﬁdence interval (CI) 99 000–250 0000) in 2000 to
78 000 (95% CI 41 000–126 000) in 2010.5 In the past few decades,
an increase in drug resistance rates to ﬁrst-line anti-TB drugs and
multidrug resistance has been observed in several provinces of
China.6–8
A recent report from China demonstrated that the majority of
MDR-TB cases in some settings with a high prevalence of MDR-TB
are due to the transmission of drug-resistant bacillary strains to
previously untreated patients, rather than mismanagement of a
previous treatment episode.9 Thus, the timely detection of drug
resistance is of great importance to optimize treatment and to
direct infection control measures to block the transmission of
MDR-TB.
The objectives of this study were to analyze the prevalence and
characteristics of drug-resistant TB at a local hospital in Northeast
China, to estimate the incidence of drug-resistant TB, and to
identify factors that are linked to drug-resistant TB, especially to
MDR-TB.ociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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2.1. Study setting
A retrospective analysis of the laboratory data of patients with
TB, diagnosed between March 8, 2010 and July 13, 2011, was
undertaken at a local hospital in Northeast China. The diagnosis of
pulmonary TB in hospitals and TB clinics is made on the basis of
clinical examination, chest radiography, and sputum smear
microscopy and/or sputum culture.5,10
Throughout the survey, each newly enrolled TB patient who
was positive on sputum smear microscopy was interviewed to
obtain their treatment history. The treatment histories of the TB
patients were classiﬁed into new and previously treated cases. In
our surveys, newly treated patients were deﬁned as patients who
had never received anti-TB treatment or had received previous
treatment for less than 1 month. Previously treated patients were
deﬁned as those who had previously received anti-TB treatment
for more than 1 month.10
2.2. Drug susceptibility testing
The criteria used for MTB drug susceptibility testing have been
published previously.5,11,12 Drug susceptibility testing was per-
formed after subculturing with the use of Lo¨wenstein–Jensen
medium. Drug susceptibility was determined by means of the
proportion method, with the following concentrations for the four
ﬁrst-line anti-TB drugs and two second-line drugs in the survey:
isoniazid (INH; 0.2 mg/ml), rifampin (RIF; 40 mg/ml), ethambutol
(EMB; 2 mg/ml), streptomycin (SM; 4 mg/ml), and oﬂoxacin (OFL;
2 mg/ml) with kanamycin (KAM; 40 mg/ml). A positive result was
deﬁned by the growth of more than 1% of colonies compared to the
drug-free control.
Any drug resistance (ADR) was deﬁned as resistance to any of
the anti-TB drugs (INH, RIF, EMB, SM, and OFL or KAM). Multidrug
resistance (MDR) was deﬁned as bacillary resistance to at least INH
and RIF. Extensive drug resistance (XDR) was deﬁned as MDR-TB
with additional bacillary resistance to any ﬂuoroquinolone and atTable 1
Prevalence of ﬁrst-line and second-line anti-tuberculosis drug resistance in a local hos
Resistance proﬁle Newly treated patients
(n = 164), n (%)
Susceptible 128 (78.0) 
Any resistancea (total) 36 (22.0) 
INH 14 (8.5) 
RIF 12 (7.3) 
EMB 11 (6.7) 
SM 19 (11.6) 
OFL 6 (3.7) 
KAM 2 (1.2) 
Mono-resistanceb (total) 22 (13.4) 
INH 5 (3.0) 
RIF 2 (1.2) 
EMB 4 (2.4) 
SM 6 (3.7) 
OFL 4 (2.4) 
KAM 1 (0.6) 
Poly-resistance,c non-MDR (total) 9 (5.5) 
INH + other drugs (except RIF) 4 (2.4) 
RIF + other drugs (except INH) 5 (3.0) 
MDRd 5 (3.0) 
XDRe 1 (0.6) 
INH, isoniazid; RIF, rifampin; EMB, ethambutol; SM, streptomycin; OFL, oﬂoxacin; KAM
a Any resistance: resistance to any of the anti-TB drugs.
b Mono-resistance: resistance to only one drug.
c Poly-resistance: resistance to at least two or more drugs, but excluding the INH an
d MDR: resistance to at least INH and RIF.
e XDR: resistance to at least INH, RIF, OFL, and KAM.least one second-line injectable drug (amikacin, capreomycin, or
KAM). Mono-resistance was deﬁned as resistance to only one drug,
and poly-resistance was deﬁned as resistance to at least two or
more drugs excluding the INH and RIF combination.13,14
2.3. Data analysis
The statistical package SPSS 13.0 (SPSS Inc., Chicago, IL, USA)
was used to analyze the data. A p-value of less than 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Prevalence of drug resistance
Among 205 patients, 164 (80%) were newly diagnosed patients
and 41 (20%) were previously treated. The age of TB patients was
mainly concentrated in the 15–44 years age group. Drug resistance
levels are shown in Table 1. Of the total 205 patients, 26.3% had
resistance to at least one of the tested anti-TB drugs. Twenty-two
percent (36/164) of new TB cases and 43.9% (18/41) of previously
treated patients had TB resistant to any of the four ﬁrst-line and
two second-line anti-TB drugs, thus previously treated patients
were more likely to harbor drug resistance compared to newly
treated cases (Chi-square = 8.76, p < 0.01).
A total of 29.3% of previously treated cases had TB resistant to
INH, 26.8% to RIF, 24.4% to SM, and 19.5% to EMB; 11.6%, 8.5%, 7.3%,
and 6.7% of newly treated cases had resistance to SM, INH, RIF, and
EMB, respectively.
The ADR, mono-resistance, and poly-resistance (non-MDR)
rates of the newly treated cases were 22.0%, 13.4%, and 5.5%,
respectively. The ADR, mono-resistance, and poly-resistance (non-
MDR) rates of the previously treated cases were 43.9%, 17.1%, and
4.9%, respectively. In addition, among all patients there were 14
cases (6.8%) with MDR-TB, of which 3.0% were newly treated cases
and 22% were previously treated cases. Importantly, an XDR isolate
was found, which was isolated from a newly treated patient.pital of Northeast China, 2010–2011
Previously treated patients
(n = 41), n (%)
All cases
(n = 205), n (%)
23 (56.1) 151 (73.2)
18 (43.9) 54 (26.3)
12 (29.3) 26 (12.7)
11 (26.8) 23 (11.2)
8 (19.5) 19 (9.3)
10 (24.4) 29 (14.1)
4 (9.8) 10 (4.9)
1 (2.4) 3 (1.5)
7 (17.1) 29 (14.1)
2 (4.9) 7 (3.4)
1 (2.4) 3 (1.5)
1 (2.4) 5 (2.4)
2 (4.9) 8 (3.9)
1 (2.4) 5 (2.4)
0 1 (0.5)
2 (4.9) 11 (5.4)
1 (2.4) 5 (2.4)
1 (2.4) 6 (2.9)
9 (22.0) 14 (6.8)
0 1 (0.5)
, kanamycin.
d RIF combination.
Table 2
Any drug resistance by age group and gender group
Variable All isolates, n Any drug resistance, n (%) p-Value
Age group, years
0–14 2 0
15–44 113 33 (29.2)
45–64 71 16 (22.5)
>64 19 5 (26.3) 0.608a
Gender
Male 145 40 (27.6)
Female 60 14 (23.3) 0.529b
a Comparison of 15–44 and 45–64 years age group patients and >64 years age
group patients.
b Male gender group vs. female gender group.
Table 3
Multidrug resistance by age group and gender group
Variable All isolates, n Multidrug resistance, n (%) p-Value
Age group, years
0–14 2 0
15–44 113 11 (9.7)
45–64 71 3 (4.2) 0.175a
>64 19 0
Gender
Male 145 12 (8.3)
Female 60 2 (3.3) <0.001b
a Patients in the 15–44 years age group vs. patients in the 45–64 years age group.
b Male gender group vs. female gender group.
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resistant TB
Of all 205 isolates, 113 (55.1%) were from patients aged 15–44
years. We observed that the proportion of ADR-TB cases in 15–44-
year-old patients was slightly higher than in the other age groups
(Table 2). Moreover, 70.7% (n = 145) of the patients were male and
the proportion of ADR-TB was higher in males than in females,
although no signiﬁcant difference was found (27.6% vs. 23.3%; Chi-
square = 0.396, p = 0.529). Compared with females, males were
more likely to develop MDR-TB (8.3% vs. 3.3%; Chi-square = 8.69,
p < 0.001) (Table 3).
3.3. Resistance patterns in patients diagnosed between 2010 and 2011
The differences in resistance rates to the four ﬁrst-line and two
second-line drugs against TB between 2010 and 2011 are shown in
Figure 1. The resistance rate to SM was 15.7% in 2010, and it
decreased to 11.5% in 2011. A similar decrease was seen in the
resistance rates to RIF and EMB. In contrast, the prevalence of TB
isolates resistant to OFL increased from 2.9% to 3.8% from 2010 to
2011. However, there were no signiﬁcant differences between
2010 and 2011 (p > 0.05).Figure 1. Drug resistance rates for TB patients diagnosed in 2010 and 2011 at a local
hospital in Harbin, Northeast China.4. Discussion
China is a country with a high burden of TB and a hot spot region
for MDR-TB infection.15 Our study reports the rates of drug
resistance including MDR-TB in a local hospital of Northeast China.
Overall, 26.3% of the isolates were resistant to at least one ﬁrst-line
anti-TB drug, which is close to the level of the reported national
proportion (24.3%). The MDR prevalence rates found in this study
(overall 6.8%; 3.0% and 22.0% among new cases and previously
treated cases, respectively) are similar to the national average
(overall 6.8%; 5.4% among new cases and 15.4% among previously
treated cases),5 and higher than the global average of 5.2%.3
Compared to the province median level (MDR 7.2% among newly
treated cases and 30.4% among previously treated cases),16
resistance was relatively lower among patients in the hospital.
This phenomenon might have appeared for two reasons. First, the
results might contribute to the introduction of programmatic
management of drug-resistant TB (PMDT). Second, TB patients
could receive relatively better treatment in this area, as Harbin
(where the hospital is located) has the best public health system
and best hospital system in the province.
If a city has an effective TB control program, the proportion of
previously treated patients should be low.17 In this study, the
proportion of previously treated patients was 20%, which is close to
the national average, but much higher than the global median of
11%.3 The results also show that previously treated patients were
more likely to harbor drug-resistant TB and MDR-TB than new
cases, and the proportion of previously treated patients with MDR-
TB was seven times higher than that of new cases. These results
agree with the previous conclusion that in a well functioning TB
control program with low levels of default from treatment, high
resistance levels are expected among previously treated cases
because drug resistance is a strong risk factor for recurrent TB.8
This study showed that, in addition to patients with MDR-TB,
9.7% of the newly treated patients and 12.2% of previously treated
cases had disease that was resistant to either INH or RIF, placing
them just one step away from having MDR-TB. The current
investigation found a newly treated patient suffering from XDR-TB.
XDR-TB is associated with high morbidity and mortality and
requires individualized treatment to accurately address both ﬁrst-
line and second-line treatment resistance.18,19 However, surveil-
lance data on XDR-TB from China remain scarce.20 In the coming
years, China plans to expand an effective treatment program for
MDR-TB that is modeled on international best practice.9,21
We found that resistance rates to SM, INH, and RIF were
signiﬁcantly higher than EMB and second-line anti-TB drugs,
which was expected, because these three drugs were introduced in
China earlier than the other drugs.22 In addition, we could not
conﬁrm whether or not patients in Harbin had abused those drugs
(causing default on treatment) more than the patients in other
provinces. This result is consistent with previous reports from
China, India, and the UK.8,13,23,24 It is noteworthy that the rate of
resistance to EMB was obviously higher than the national level
(9.3% vs. 1.5%),8 which may be due to the excessive use of this drug
in recent years. Our study found a high level of resistance to all four
ﬁrst-line anti-TB drugs and low-level resistance to second-line
anti-TB drugs.
Certain groups of patients were more likely to develop drug-
resistant TB. In this study, males were more prone to suffer from
drug-resistant TB and had a signiﬁcantly higher proportion of
multidrug resistance compared with females. The results of this
survey support previous studies that have shown signiﬁcantly higher
TB incidence in males than females, which may reﬂect a genuine sex
difference in TB susceptibility, or behavioral differences.25 Thus,
gender issues should be considered in promoting health-care seeking
behavior in patients and to reduce diagnostic delays.
Y. Yang et al. / International Journal of Infectious Diseases 22 (2014) 83–8686There are several limitations to this study. First, our data were
only collected from a local hospital, which might not truly reﬂect
the whole population of Northeast China. Second, information on
previous treatment was based only on interviews with the
patients; this may have resulted in inaccurate information
regarding treatment. Third, no molecular data were available to
provide additional evidence of relapse with drug-resistant MTB
versus the spread of multi-resistant clones.
In conclusion, the rate of drug-resistant TB in the hospital was
close to the national average. Certain people, including previously
treated patients and male patients, were more likely to develop
drug-resistant TB. Further work is required in the local hospital to
more fully understand the social and environmental determinants
that contribute to the high transmission rates before early
detection technology and the provision of effective treatment. It
is also essential to carry out a systematic study on the relationship
between genotype and drug resistance in the future.
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